The compound, designated as DT-109, operates by suppressing harmful bacterial populations within the gastrointestinal tract, fortifying the intestinal lining, and effectively intercepting inflammatory substances before they can migrate to the liver. According to findings recently published in The Journal of Clinical Investigation, this gut-centric therapeutic approach successfully reversed metabolic dysfunction-associated steatohepatitis (MASH) in both mice and nonhuman primates. The breakthrough introduces a promising new strategy for managing a complex disease that has long frustrated medical professionals due to a lack of effective pharmaceutical interventions.
MASH currently affects approximately 7% of the global population. It represents an advanced, severe stage of non-alcoholic fatty liver disease characterized by the pathological accumulation of excess fat within the liver, which subsequently triggers chronic inflammation and cellular injury. Over time, persistent tissue injury can drive the condition forward into cirrhosis, a debilitating state defined by extensive liver scarring, as well as elevate the risk of primary liver cancer and total liver failure. Although clinical care standards and diagnostic methods have advanced incrementally in recent years, robust and universally effective medical therapies remain critically limited.
"We see clear evidence that DT-109 protects the gut epithelial barrier, reducing the systemic influx of harmful microbial products that are thought to contribute to MASH development and progression," said Eugene Chen, M.D., Ph.D., senior author of the study and the Frederick G. L. Huetwell Professor of Cardiovascular Medicine at the University of Michigan Medical School. "This compound shows benefits to the gastrointestinal system and has great potential as a treatment for MASH."
How Harmful Gut Bacteria Can Trigger Liver Damage
Dr. Chen’s research team had previously established that DT-109—a glycine-based tripeptide—could alleviate MASH symptoms in preliminary animal evaluations. A tripeptide is a relatively small molecule constructed from three amino acids, which serve as the fundamental building blocks of proteins within biological systems. However, the precise biochemical mechanisms by which the compound exerted these protective effects remained poorly understood.
The latest research clarifies this missing link, mapping out how shifts in the gut microbiome can initiate a destructive biological chain reaction that ultimately culminates in severe hepatic injury, and demonstrating precisely how DT-109 interrupts that cascade.
Before assessing the therapeutic efficacy of the drug, the investigators isolated and confirmed a primary driver of the pathology: the overgrowth of Clostridium perfringens, a bacterium known to generate high concentrations of ammonia within the intestinal lumen. As local ammonia concentrations rise, they begin to compromise the structural integrity of the gut’s protective inner lining. Under healthy physiological conditions, this intestinal epithelial barrier acts as a selective filter, preventing potentially toxic or foreign substances native to the digestive tract from leaking into the systemic circulation.
As this biological barrier weakens, however, microbial toxins and metabolic byproducts generated by gut bacteria escape the digestive system and travel directly to the liver via the portal vein. Once inside the hepatic environment, these circulating toxins provoke intense local inflammation and trigger hyper-reactive immune responses that accelerate tissue damage.
Part of this destructive response involves the hyperactivation of CD8+ T cells, specialized immune cells that normally protect the body by destroying virus-infected or abnormal cells. When these immune cells become aberrantly overactive within the liver, they significantly intensify the chronic inflammatory cycles characteristic of MASH. These insights illuminate why a pathology traditionally diagnosed and observed within the liver can be heavily dictated by events unfolding elsewhere in the human digestive system.
Experimental Drug Repairs the Gut and Protects the Liver
Through a meticulously controlled sequence of experiments, the Michigan Medicine team discovered that DT-109 disrupts this pathological feedback loop by rebalancing the intestinal microenvironment and actively reinforcing the gut barrier.
In laboratory evaluations involving both mice and nonhuman primates, administration of the compound successfully suppressed populations of Clostridium perfringens and reduced overall ammonia production inside the intestines. These microbiological shifts allowed the intestinal lining to repair and strengthen itself, severely restricting the translocation of harmful microbial substances into the bloodstream and shielding the liver from subsequent chemical injury.
The therapeutic results were particularly striking in nonhuman primate models, whose underlying liver physiology and gut microbiome compositions closely mirror those of humans far more accurately than standard murine models. In these primates, DT-109 measurably diminished hepatic inflammation and reversed the clinical severity of MASH.
Together, these observations demonstrate how intervening in localized processes within the gastrointestinal tract can yield profound, systemic benefits for distant organs, illustrating the power of targeting the gut-liver axis.
"DT-109 connects microbiota modulation with liver protection by restoring gut barrier integrity and limiting the systemic translocation of ammonia and other pro-inflammatory microbial products within the gut-liver axis," said Jifeng Zhang, Ph.D., co-author and research professor of cardiovascular medicine at the U-M Medical School. "We also found that DT-109 primarily acts in the gastrointestinal tract, but its reach stretches much further."
The gut-liver axis describes the intricate physiological and anatomical communication network linking the digestive system and the liver. Because venous blood draining the intestines flows directly into the liver, hepatic health is exceptionally sensitive to fluctuations in gut bacteria composition and intestinal permeability. By targeting this biological bridge, DT-109 offers a novel paradigm for intercepting the root drivers of liver inflammation rather than merely treating structural damage after it has occurred.
Potential Benefits Beyond Fatty Liver Disease
Given its capacity to preserve intestinal barrier function and mitigate systemic inflammation, researchers believe DT-109 may hold therapeutic value for a wider spectrum of metabolic and inflammatory disorders.
Previous investigations led by the same group revealed that DT-109 can significantly inhibit the formation of atherosclerotic plaques and prevent vascular calcification in nonhuman primates. Atherosclerosis involves the hazardous accumulation of fats, cholesterol, and cellular debris within arterial walls, which restricts blood flow and escalates the risk of acute cardiovascular events like heart attacks and strokes. Similarly, vascular calcification occurs when mineral deposits harden blood vessel walls, reducing vascular elasticity and compounding cardiovascular risk.
These findings suggest that DT-109 could eventually provide dual-action therapies capable of addressing both liver disease and cardiovascular complications concurrently—an encouraging prospect given that metabolic disorders frequently affect multiple organ systems simultaneously.
Furthermore, the research team is actively exploring whether the compound might offer relief for individuals suffering from inflammatory bowel disease (IBD), a category of chronic gastrointestinal conditions that includes Crohn’s disease and ulcerative colitis. Because compromised intestinal barrier integrity is a hallmark of numerous gastrointestinal disorders, a pharmacological agent capable of reinforcing this barrier could theoretically benefit patients suffering from various forms of gut inflammation. However, the researchers emphasize that dedicated, specialized studies will be required to validate the drug’s efficacy in those specific contexts.
A Promising Treatment That Still Needs Human Trials
Despite the overwhelmingly positive preclinical data, DT-109 remains an experimental therapeutic agent. Its capacity to halt and reverse MASH has been robustly documented in animal models, but clinical investigators have not yet established whether the compound can safely and effectively produce comparable outcomes in human patients.
The next critical phase of the research initiative will focus on comprehensive preclinical safety evaluations and preparations to transition the compound into formal human clinical trials. These upcoming human studies will be essential for determining optimal dosing parameters, establishing overall safety profiles, and verifying therapeutic efficacy in clinical populations.
"This study presents novel evidence about the pathogenesis of MASH and provides excitement about a therapeutic avenue to explore for a condition that remains difficult to treat," said Elliot Tapper, M.D., Academic Director of Hepatology at Michigan Medicine. "What patients with MASH need is a safe and effective therapy capable of improving their liver and heart health—of course we are excited about these developments."
This discovery underscores a fundamental conceptual shift in how biomedical researchers are approaching complex metabolic liver diseases. By focusing on the modulation of harmful gut microbes and the restoration of the intestinal epithelial barrier, scientists may soon be able to protect and heal the liver using treatments that exert their primary therapeutic actions outside the organ itself.
If subsequent human clinical trials successfully replicate the beneficial outcomes observed in animal studies, DT-109 could introduce an entirely new class of targeted therapies for severe fatty liver disease while simultaneously offering protection against interconnected cardiovascular complications.
The underlying research received support from institutional grants and was conducted in strict compliance with ethical guidelines for animal welfare and clinical protocol standards. Ying Zhao, Oren Rom, Jifeng Zhang, and Y. Eugene Chen are named as inventors on a pending patent application covering tripeptides and their use in treating metabolic, cardiovascular, and inflammatory disorders. Dr. Chen is also recognized as an inventor of DT-109. The University of Michigan holds the intellectual property rights for the compound and has licensed the technology to Diapin Therapeutics, an enterprise in which both Dr. Chen and the university maintain financial ownership interests. Diapin Therapeutics supplied the DT-109 material utilized in the study and continues to oversee its clinical development pipeline.